Clinical Trial Setback Sends Intellia Shares Plummeting

Intellia Therapeutics faced a severe market downturn following the disclosure of a patient death in a pivotal Phase 3 clinical trial. The biotechnology firm’s stock experienced a dramatic collapse, plummeting an additional 27% during after-hours trading after already closing the regular session with a 9% decline.

The devastating news emerged from the MAGNITUDE study evaluating the company’s lead candidate, nexiguran ziclumeran (nex-z). This CRISPR-based therapeutic targets transthyretin amyloidosis, a progressive and frequently fatal condition. On November 6, CEO John Leonard confirmed the passing of a participant who had previously developed severe liver complications. Leonard expressed that the company was “deeply affected to learn the patient with Grade 4 liver transaminase elevations passed away Read more...